PharmaEngine

PharmaEngine Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of PharmaEngine (4162.TWO) as of Nov 12, 2026 is 0.02. In the previous year, Net Debt to Free Cash Flow Ratio was -14.11 — a change of -100.11% (higher).

Net Debt/FCF

0.02

YoY

-100.11%

Last updated:

Net Debt to Free Cash Flow Ratio of PharmaEngine is 2024 0.02 . Net Debt to Free Cash Flow Ratio of PharmaEngine was 2023 -14.11 . It decreases by -100.11% higher compared to the previous year.

The PharmaEngine Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2017
9.65 TWD
Jan 1, 2018
-4.92 TWD
Jan 1, 2019
-213.15 TWD
Jan 1, 2020
-52.55 TWD
Jan 1, 2021
-4.10 TWD
Jan 1, 2022
-18.37 TWD
Jan 1, 2023
-14.11 TWD
Jan 1, 2024
0.02 TWD
The PharmaEngine Net Debt/FCF history
YEARNet Debt/FCFYoY
0.02-100.11%
-14.11-23.18%
-18.37+348.65%
-4.10-92.21%
-52.55-75.35%
-213.15+4,233.69%
-4.92-150.98%
9.65-314.53%
-4.50-37.78%
-7.23-67.34%
-22.13—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

Net Debt to Free Cash Flow Ratio of PharmaEngine is 0.02 in 2024.

Net Debt to Free Cash Flow Ratio of PharmaEngine changed from -14.11 to 0.02, representing a -100.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's PharmaEngine with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — PharmaEngine

All Key Metrics — PharmaEngine